Trials / Completed
CompletedNCT05288881
Single Ascending Dose Study of ANX105
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX105 in Normal Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Annexon, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ANX105 administered intravenously (IV) to healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ANX105 | Participants will receive single-ascending doses of ANX105 administered by IV infusion. |
| DRUG | Placebo | Participants will receive matching placebo administered by IV infusion. |
Timeline
- Start date
- 2022-02-28
- Primary completion
- 2023-06-19
- Completion
- 2023-06-19
- First posted
- 2022-03-21
- Last updated
- 2024-08-19
Locations
2 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05288881. Inclusion in this directory is not an endorsement.